Ocular Therapeutix insider filing reveals CCO’s 152.7k shares, 512k option grants

Rhea-AI Filing Summary

On 06/11/2025, Ocular Therapeutix (OCUL) Chief Commercial Officer Steve Lawrence Meyers filed a Form 3, establishing his initial beneficial ownership. He directly owns 152,728 common shares, including 117,317 unvested RSUs granted in 2023-2025 under the company’s 2021 Stock Incentive Plan. In addition, Meyers holds four option grants totaling 512,000 shares with strike prices ranging from $3.88 to $7.44 and expirations between 2032-2035; each option vests monthly over four years. The filing is routine, reflects no open-market purchases or sales, and does not alter the company’s capital structure.

Insights

Securities Analyst

TL;DR Form 3 shows CCO holds 152.7k shares and 512k options; administrative disclosure, no buy/sell action, neutral investor impact.

This Form 3 merely documents the equity position of a newly designated Section 16 officer. The disclosed holdings—roughly 0.2% of OCUL’s basic shares outstanding—align the CCO’s incentives with shareholders but do not represent a transaction or signal on valuation. All derivative securities are option grants from prior compensation plans, with strikes mostly above the recent trading range, so near-term dilution risk is negligible. Overall, the filing is non-material and should not influence valuation models or trading strategy.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Meyers Steve Lawrence

(Last) (First) (Middle)

C/O OCULAR THERAPEUTIX, INC.

15 CROSBY DRIVE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/11/2025

3. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	152,728(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	04/03/2032	Common Stock	45,000	$5.22	D
Stock Option (Right to Buy)	(3)	01/29/2033	Common Stock	100,000	$3.88	D
Stock Option (Right to Buy)	(4)	02/02/2034	Common Stock	145,000	$5.18	D
Stock Option (Right to Buy)	(5)	02/10/2035	Common Stock	222,000	$7.44	D

Explanation of Responses:

1. Includes 11,111 restricted stock units ("RSUs") remaining unvested pursuant to an award of 33,333 RSUs granted under the 2021 Stock Incentive Plan, as amended (the "Plan"), of Ocular Therapeutix, Inc. (the "Corporation") on January 30, 2023; 32,206 RSUs remaining unvested pursuant to an award of 48,309 RSUs granted under the Plan on February 3, 2024; and 74,000 RSUs remaining unvested pursuant to an award of 74,000 RSUs granted under the Plan on February 11, 2025. Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the respective date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.

2. This option was granted on April 4, 2022 and vests over four years, with 1/4 of the shares underlying the option having vested on March 15, 2023 and 1/48 of the shares vesting monthly thereafter.

3. This option was granted on January 30, 2023 and vests over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the grant date.

4. This option was granted on February 3, 2024 and vests over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the grant date.

5. This option was granted on February 11, 2025 and vests over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the grant date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Todd Anderman, Attorney-in-Fact for Steve Lawrence Meyers	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many OCUL common shares does Steve Meyers beneficially own?

He reports 152,728 directly owned common shares, including unvested RSUs.

What derivative securities are disclosed in the OCUL Form 3?

Meyers holds 4 stock-option grants covering a total of 512,000 shares, with strikes from $3.88 to $7.44 and expirations 2032-2035.

When do Steve Meyers’ RSUs vest?

The RSUs vest in three equal annual installments beginning on the one-year anniversary of each respective grant date (2023-2025 awards).

What event triggered the Form 3 filing for OCUL?

Designation as a Section 16 reporting person on 06/11/2025 required the initial ownership statement.

What is Steve Meyers’ role at Ocular Therapeutix?

He is the company’s Chief Commercial Officer, serving as both an officer and director-level insider.